|
Market Closed -
Nasdaq
16:00:00 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 5.020 USD | -0.20% |
|
+4.15% | +76.14% |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Oramed Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 208.8 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 84.08% |
| Enterprise Value (EV) | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 208.8 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 84.08% |
| P/E | -46.1x | -12.8x | 16.5x | -5.04x | 1.9x | 1.12x |
| PBR | - | - | - | - | - | - |
| PEG | - | -0x | -0x | 0x | -0x | 0x |
| Capitalization / Revenue | 602x | 174x | 69.5x | - | 56.7x | - |
| EV / Revenue | 0x | 0x | 0x | - | 0x | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -9.04x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.31 | -0.94 | 0.14 | -0.48 | 1.5 | 4.47 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.904 | 2.703 | 1.34 | - | 2 | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -40.6 | -15.77 | -12.78 | -15.09 | -23.1 |
| Net income 1 | - | -36.56 | 5.525 | -19.06 | 64.05 | 188.6 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 14.280 | 12.030 | 2.310 | 2.420 | 2.850 | 5.020 |
| Nbr of stocks (in thousands) | 38,086 | 39,115 | 40,339 | 40,312 | 39,802 | 41,597 |
| Announcement Date | 3/30/22 | 3/6/23 | 3/6/24 | 3/27/25 | 3/26/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 1.12x | - | - | - | 209M | |
| 33.86x | 6.04x | 17.97x | 0.95% | 49.81B | |
| -21.01x | 245.16x | -22.36x | -.--% | 44.06B | |
| 33.64x | 3.26x | 14.08x | -.--% | 42.99B | |
| 47.1x | 5.45x | 29.8x | -.--% | 40.88B | |
| 28.69x | 8.67x | 21.92x | 0.4% | 33.11B | |
| 33.78x | 5.53x | 25.14x | -.--% | 16.58B | |
| 24.18x | 2.1x | 9.1x | 1.11% | 14.63B | |
| 77.11x | 4.06x | 15.74x | -.--% | 13.76B | |
| Average | 28.72x | 35.03x | 13.92x | 0.31% | 28.45B | |
| Weighted average by Cap. | 27.57x | 46.64x | 12.61x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORMP Stock
- Valuation Oramed Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
